Sulzer Medica launches biological implant in Europe:
This article was originally published in Clinica
Sulzer Medica has launched its first biological implant, the collagen meniscus implant, CMI, in Europe. The product is a sponge-like structure of highly purified collagen. The porous structure of the CMI serves as a scaffold to support ingrowth of cells and the formation of new meniscus tissue. The product was developed jointly with Redwood, California-based ReGen Biologics, in which Sulzer has a minority holding. Sulzer, of Winterthur, Switzerland, has marketing and distribution rights to the product worldwide, excluding the US.
You may also be interested in...
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.